Status: Recruiting
Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis
The primary objective of the study is to evaluate the effectiveness of Ravulizumab in improving MG-ADL in an early-stage AChR+ gMG population.
Participants needed: 40
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Alexion Pharmaceuticals, Inc.Updated: Feb 5, 2026Locations: 23
Eligibility criteria
History of a positive serologic test for anti-AChR antibodies, and [+7]
Patient unable to understand and sign the informed consent [+10]